January 12-15, 2026 | San Francisco Marriott Marquis, CA
KAHR Medical develops novel bi-functional, immunotherapeutic fusion proteins for the treatment of cancer. Our lead compound, DSP107 is in a phase 2b trial in fourth line metastatic colorectal cancer.